IMMUNE PROFILES TO DISTINGUISH HOSPITALIZED VERSUS AMBULATORY COVID-19 CASES IN OLDER PATIENTS

Jéromine Klingler^{1,2}, Gregory S. Lambert¹, Juan C. Bandres^{1,2}, Rozita Emami-Gorizi², Arthur Nádas³,
 Kasopefoluwa Y. Oguntuyo⁴, Fatima Amanat^{4,5}, PARIS Study Team^{4,6}, Viviana Simon^{1,4,6,7,8}, Benhur
 Lee⁴, Susan Zolla-Pazner^{1,4}, Chitra Upadhyay¹, Catarina E. Hioe^{1,2,4*}

¹Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New
 York, NY, USA

- 10 ²James J. Peters VA Medical Center, Bronx, NY, USA
- ³Department of Environment Medicine, NYU School of Medicine, New York, NY, USA
- ⁴Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ⁵Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY,
 USA
- ⁶Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai,
 New York, NY, USA
- ⁷Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York,
 NY, USA
- ⁸Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New
 York, NY, USA
- 21

1 2

3

4

- 22
- 23 *Co-corresponding author
- 24 Contact: catarina.hioe@mssm.edu, catarina.hioe@va.gov
- 25

26 Abstract

- 27 Background: A fraction of COVID-19 patients develops severe disease requiring hospitalization, while
- 28 the majority, including high-risk individuals, experience mild symptoms. Severe disease has been
- 29 associated with higher levels of antibodies and inflammatory cytokines, but the association has often
- 30 resulted from comparison of patients with diverse demographics and comorbidity status. This study

examined patients with defined demographic risk factors for severe COVID-19 who developed mild vs.
severe COVID-19.

33	Methods: This study evaluated hospitalized vs. ambulatory COVID-19 patients in the James J. Peters VA
34	Medical Center, Bronx, NY. This cohort presented demographic risk factors for severe COVID-19:
35	median age of 63, >80% male, >85% black and/or Hispanic. Sera were collected four to 243 days after
36	symptom onset and evaluated for binding and functional antibodies as well as 48 cytokines/chemokines.
37	Findings: Ambulatory and hospitalized patients showed no difference in SARS-CoV-2-specific antibody
38	levels and functions. However, a strong correlation between anti-S2 antibody levels and the other antibody
39	parameters was observed in hospitalized but not in ambulatory cases. Cytokine/chemokine levels also
40	revealed differences, with notably higher IL-27 levels in hospitalized patients. Hence, among the older,
41	mostly male patients studied here, SARS-CoV-2-specific antibody levels and functions did not distinguish
42	hospitalized and ambulatory cases but a discordance in S2-specific antibody responses was noted in
43	ambulatory patients, and elevated levels of specific cytokines were maintained in convalescent sera of
44	hospitalized cases.
45	Interpretation: The data indicate that antibodies against the relatively conserved S2 spike subunit and
46	immunoregulatory cytokines such as IL-27 are potential immune determinants of COVID-19.
47	
48	Keywords
49	SARS-CoV-2, COVID-19, high-risk population, antibodies, cytokines, IL-27
50	
51	Research in context
52	Evidence before this study: Previous studies demonstrated that high levels of SARS-CoV-2 spike
53	binding antibodies and neutralizing antibodies were associated with COVID-19 disease severity.

54 However, the comparisons were often made without considering demographics and comorbidities.

- 55 Correlation was similarly shown between severe disease and marked elevation of several plasma cytokines
- 56 but again, most analyses of cytokine responses to COVID-19 were conducted by comparison of patient
- 57 cohorts with diverse demographic characteristics and risk factors.
- 58 Added value of this study: We evaluated here a comprehensive profile of SARS-CoV-2-specific
- 59 antibodies (total Ig, isotypes/subtypes, Fab- and Fc-mediated functions) and a panel of 48 cytokines and
- 60 chemokines in serum samples from a cohort of SARS-CoV-2-infected patients with demographic risk
- 61 factors for severe COVID-19: 81% were male, 79% were >50 years old (median of 63), and 85%
- 62 belonged to US minority groups (black and/or Hispanic). Comparison of hospitalized vs. ambulatory
- 63 patients within this cohort revealed two features that differed between severe vs. mild COVID-19 cases: a
- 64 discordant Ab response to the S2 subunit of the viral spike protein in the mild cases and an elevated
- 65 response of specific cytokines and chemokines, notably IL-27, in the severe cases.
- 66 Implications of all the available evidence: Data from the study identified key immunologic markers for
- 67 severe vs. mild COVID-19 that provide a path forward for investigations of their roles in minimizing or
- 68 augmenting disease severity.
- 69

70 Background

71 The emergence and rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 72 Wuhan, China, in December 2019 has led to a pandemic that continues to impact people worldwide. 73 While research about this virus has progressed rapidly, leading to expeditious development of many types 74 of diagnostic tests, treatments, and vaccines, important questions remain about the dynamic virus-host 75 interactions that result in a wide range of disparate disease outcomes. 76 Coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2, can occur with different 77 clinical manifestations. During the initial outbreak in China, most patients presented with mild to 78 moderate symptoms which resolved without medical interventions, but $\sim 15\%$ of patients progressed 79 rapidly to severe disease requiring hospitalization (1,2). Among the hospitalized, patients also require 80 different levels of intervention. Around a third of hospitalized patients developed acute respiratory disease 81 syndrome (ARDS) and require mechanical ventilation (3). Elderly patients and individuals with

82 comorbidities, such as cardiovascular disease, diabetes mellitus, chronic lung disease, chronic kidney

83 disease, obesity, hypertension, and cancer, have a much higher mortality rate than healthy younger adults

84 (4). In addition, the overall COVID-19 case-fatality ratio is at least 2.4 times higher in men than in women

85 (5–7).

86 Understanding the immune responses associated with disease severity and recovery is essential to develop 87 and apply effective treatments against COVID-19. While high levels of binding antibodies (Abs), in 88 particular IgA, and neutralizing Abs have been associated with disease severity (8–10), comparison of 89 severe and mild cases was often without consideration for age, sex, and comorbidities. Indeed, a study of 90 infected patients from a wide range of age groups (1-102 years) demonstrated that anti-SARS-CoV-2 Ab 91 levels varied depending on age (11). The levels in the 1-10 years old group were around three- to four-fold 92 higher than the 25-102 years old groups. Another study comparing SARS-CoV-2-infected male and 93 female patients from diverse ethnic groups showed no difference in Ab titers (12). However, male patients

94 had higher plasma levels of innate immune cytokines and more robust induction of non-classical

- 95 monocytes, while female patients developed significantly more robust T cell activation (12). IgG Fc
- 96 glycome composition was also shown to predict disease severity but comparison was within a patient
- 97 cohort that included both sexes and had an age range of 21 to 100 years old (13).
- 98 In addition to Abs, cytokine responses in severe vs. mild COVID-19 cases have been evaluated. An

99 association was shown between SARS-CoV-2 infection and marked elevation of several plasma cytokines

- 100 including interferon gamma-induced protein 10 (IP-10), chemokine (C-X-C motif) ligand 16 (CXCL16),
- 101 interleukin (IL)-1 β , IL-2R, IL-4, IL-6, IL-8, IL-10 and IL-17 (10,14–21). Several other studies provided
- 102 evidence that type I interferon deficiency may lead to severe COVID-19, implying that disease severity
- 103 may be due to impaired viral clearance and uncontrolled viral replication due to poor induction of early

104 innate immunity (15,22–26). Another study revealed a positive association of the illness duration in severe

- 105 cases with levels of IL-8 and soluble IL-2R α (27). Further, a longitudinal study on 40 hospitalized
- 106 COVID-19 patients found 22 cytokines that were correlated with disease severity (28). Yet, in a study
- 107 looking at cytokine and leukocyte profile of COVID-19 patients >60 vs. <60 years old, another set of

108 cytokines/chemokines was found to correlate with older age, longer hospitalization, and a more severe

109 form of the disease (29). Similar to the Ab studies, most analyses of cytokine responses to COVID-19

110 were conducted by comparison of patient cohorts with diverse demographics and risk factors.

Further investigations of Ab and cytokine responses to SARS-CoV-2 among racial/ethnic minority US populations at risk of developing severe COVID-19 are warranted. Indeed, a study among US veterans showed that black and Hispanic individuals have experienced an excess burden of SARS-CoV-2 infection that was not entirely explained by underlying medical conditions or where they lived or received care (30). Immune responses to vaccinations also are influenced by host genetic and demographic variables such as race, ethnicity, and sex, as demonstrated by induction of higher neutralizing Ab titers following rubella vaccination in individuals of African descent as compared to the European and Hispanic subjects,

although the cytokine responses were comparable (31).

119	Here, we evaluated SARS-CoV-2-specific (spike, RBD, S1, S2, nucleoprotein) Ab responses and
120	conducted multiplex analysis of cytokines and chemokines in a cohort with risk factors for severe
121	COVID-19. Of the 52 VA subjects from James J. Peters VA Medical Center (JJP VAMC), 81% were
122	male, 79% were >50 years old (median 63), and 85% belonged to US minority groups (black and/or
123	Hispanic). All were infected with SARS-CoV-2, as confirmed by diagnostic RT-PCR, during April-
124	November 2020. Convalescent serum samples collected four to 243 days post disease onset were studied.
125	We compared different categories of COVID-19 patients within this VA cohort: ambulatory (n=42) vs.
126	hospitalized (n=10) patients, COVID-19 patients with (n=24) vs. without (n=28) comorbidities. We also
127	compared a subset of specimens (n=20) from hospitalized vs. ambulatory cases that were matched based
128	on sex, time post-infection, comorbidities, and spike-specific Ig levels. In addition, pre-pandemic and
129	contemporaneous COVID-19-negative samples were studied. The data demonstrate that, in this cohort of
130	older and mostly male VA patients, hospitalized and ambulatory patients had comparable binding and
131	functional Abs, but diverged in their responses to the S2 spike subunit. Moreover, heightened levels of
132	certain cytokines were detected and maintained in convalescent sera from hospitalized vs. ambulatory
133	cases.

134

135 Methods

Recombinant proteins. SARS-CoV-2 spike (full-length external region, amino acids 1-1213) and RBD
(amino acids 319-541) proteins were produced as described before (32,33). S1 (amino acids 16-685), S2
(amino acids 686-1213), and nucleoprotein (amino acids 1-419) antigens were purchased from ProSci Inc,
CA (catalog #97-087, #97-079 and #97-085, respectively). All antigens were of SARS-CoV-2 Wuhan-Hu1 (WA1) strain.

141 Human samples. Fifty-two COVID-19-convalescent sera samples and 49 COVID-19-negative samples (38 contemporaneous and 11 pre-pandemic) were collected at JJP VAMC under IRB#BAN-1604 and the 142 JJP VAMC Quality Improvement project "Evaluation of the clinical significance of two COVID-19 143 144 serologic assays". In addition, five SARS-CoV-2 seronegative serum samples were sourced from the 145 PARIS cohort, which follows health care workers since March 2020 (IRB-20-03374, approved by the 146 Mount Sinai Hospital Institutional Review Board). All participants in the PARIS cohort and other research 147 protocols provided written informed consent and agreed to future research and sample sharing. Samples 148 were coded prior to processing, testing, and sharing. Of the COVID-19-negative specimens, 21 were used 149 in the Ab binding and activities experiments, and 28 were used for the cytokines induction experiments. 150 Before use, all sera were heat-inactivated (30 min at 56 °C, for Ab binding and activities experiments) or 151 treated with 1% Triton X-100 (30 min at room temperature, for the cytokines induction experiments). Ab binding assay. The initial Ab evaluation was done on the Abbott Architect instrument using the 152 153 Abbott SARS-CoV-2 IgG assay, a chemiluminescent microparticle immunoassay to detect IgG against the 154 virus nucleoprotein. Subsequent Ab analyses were performed using the multiplex bead Luminex platform, 155 in which recombinant SARS-CoV-2 spike, RBD, S1, S2, and nucleoprotein antigens were coupled to 156 beads and experiments performed as described in (34,35). 157 **Neutralization.** SARS-CoV-2 pseudotyped particles (COV2pp) with spike protein of WA1 strain were 158 produced and used in neutralization assays as described before (36–38). 159 **ADCP.** Assays to measure spike-specific ADCP were performed using a published protocol (39) with 160 some modifications reported elsewhere (35). Cytokines induction. The samples were tested for 48 cytokines/chemokines by Eve Technologies 161 162 Corporation, Canada (Human Cytokine/Chemokine 48-Plex Discovery Assay® Array (HD48)). Data were

163 presented as concentrations (pg/mL) or modified Z scores. The modified Z scores used to normalize the

164 data were calculated as:

165 $Modified Z \ score = \frac{0.6745 * (Single \ data \ value - Median \ of \ the \ dataset)}{Median \ absolute \ deviation \ of \ the \ dataset}$

- Statistical analysis. Statistical analyses were performed as designated in the figure legends using
 GraphPad Prism 9 (GraphPad Software, San Diego, CA).
- 168 Role of the funding source. The study sponsors had no involvement in study design, data collection,
- 169 analysis, and interpretation, manuscript writing, and decision to submit the paper for publication.
- 170
- 171 **Results**

172 Ab responses to different SARS-CoV-2 antigens among hospitalized and ambulatory VA patients.

173 Fifty-two COVID-19-convalescent (Table 1) and 21 COVID-19-negative serum samples were collected

174 from a cohort of patients who received care at the JJP VAMC. Samples were collected between March

and December 2020, during the first year of COVID-19 pandemic in New York City. COVID-19

176 diagnosis was confirmed by positive PCR test. The vast majority of the COVID-19-convalescent subjects

177 was male (80%), Black/Hispanic (85%), and >50 years old (79%, median=63, Q1-Q3=52-74), which are

178 representative demographics of the US Veterans population. The preponderance for male and older age in

this cohort allowed for characterization of immune responses in the population known to be at risk for

180 severe COVID-19. The COVID-19 patients were categorized in two groups: hospitalized (n=10) vs.

181 ambulatory (n=42). No difference in age and race/ethnicity was observed between the hospitalized vs.

ambulatory patients (Fig 1a). However, all the hospitalized patients were male, while 10 of the 42

183 ambulatory patients were female. Analyses also considered the presence or absence of comorbidities

184 known to be associated with more severe COVID-19, which included HIV, obesity, chronic obstructive

185 pulmonary disease, diabetes, asthma, end stage renal disease or pulmonary embolism.

186 Longitudinal specimens of the COVID-19 patients were initially tested for SARS-CoV-2 nucleoprotein-

187 specific IgG (Fig 1b). These COVID-19 patients generated IgG responses against nucleoprotein, which

188	peaked around day 75 post-infection. The responses declined subsequently, but the Abs were detected
189	above cut-off up to 250 days post-infection in all except for two ambulatory patients. Samples from these
190	two patients, collected at day 27 and day 214 post-infection, although negative for nucleoprotein-specific
191	IgG (Fig 1b), were positive for spike-specific IgM and IgG, respectively (data not shown) and were both
192	positive for total Ig against spike and nucleoprotein (Fig 1c). Of note, the anti-nucleoprotein IgG levels
193	among hospitalized patients overlapped with those of ambulatory patients, and no difference was apparent
194	in the peak levels and the decline rates between the two groups (Fig 1b). There was also no apparent

195 clustering of patients with vs. without comorbidities (**Fig. 1b**).

198

The specimens collected at the last time point from each subject were available for further investigation.
The time points ranged from 4-243 days after symptom onset, with median of 178 and 188 days for

199 by hospitalized vs. ambulatory patients against spike and its domains as compared to nucleoprotein, the

hospitalized and ambulatory group, respectively (Fig 1a). To examine the relative levels of Abs induced

200 serum samples were titrated for total Ig against spike, RBD, S1, S2 and nucleoprotein antigens (Fig 1c-e

and Supplemental Fig 1). COVID-19 patients induced highly variable levels of Abs against each of the

202 five antigens tested, but all displayed Ig reactivity above cut-off (calculated as mean + three standard

203 deviations (SD) of five COVID-19-negative specimens) (Fig 1c and Supplemental Fig 1a). The S2-

specific Ab levels were relatively low (Supplemental Fig 1a), similar to past reports on other cohorts of

205 infected and vaccinated subjects (36). There was a trend of higher median levels of Abs against all five

antigens in the hospitalized group as compared to the ambulatory group, but the differences did not reach

207 statistical significance and the individual Ab levels from the two groups essentially overlapped (**Fig 1c**

and Supplemental Fig 1a), indicating that the two groups of patients could not be differentiated by their

anti-SARS-CoV-2 Ab levels. Moreover, there was no difference in the Ab levels of patients with vs.

210 without comorbidities (Fig 1d and Supplemental Fig 1b).

211	Because the sample collection times were over a wide range of days after disease onset, we searched for
212	changes in total Ig levels against each of the five SARS-CoV-2 antigens over time after disease onset (Fig
213	1e and Supplemental Fig 1c). The Ig responses to spike did not decline over the 250 days post-onset
214	(slope=56.7 and p=0.71) (Fig 1e). Ig levels against RBD and S1 also did not decrease over this period,

while the S2- and nucleoprotein-specific Ig levels demonstrated a non-significant decline (Supplemental

Fig 1c). Interestingly, when the specimens were divided according to the disease severity, the S2-specific

217 Ig levels overtime showed a trend of positive slope for the hospitalized patients and negative slope for the

ambulatory patients (Fig 1f). This pattern was not seen with Abs against S1 or RBD (data not shown).

219

220 Neutralization activities against SARS-CoV-2 among hospitalized and ambulatory VA patients. 221 COVID-19-convalescent sera were tested for neutralization activities against SARS-CoV-2 using a 222 pseudovirus bearing SARS-CoV-2 spike protein (WA1 strain) as performed previously (36–38). COVID-223 19-negative sera (n=21) were tested in parallel as control. Samples from all COVID-19-positive patients 224 had neutralization activity reaching readily above 50%, while none of the COVID-19-negative sera did (IC₅₀) <10) (**Fig 2**). Neutralization titers of hospitalized and ambulatory patients did not differ, although the sample 225 226 size of the hospitalized group was small (n=10). The IC₅₀ values ranged from 60 to 3313 for hospitalized 227 patients (median=194) and from 43 to 4402 for ambulatory patients (median=162.5). Neutralization titers 228 were also similar between groups with vs. without comorbidities associated with severe COVID-19 (Fig 229 2b). In addition, the neutralization titers showed no association with age (Fig 2c) and no decline with time 230 (Fig 2d), demonstrating that these parameters do not influence SARS-CoV-2-neutralizing titers detected in 231 sera of this VA cohort.

232

233 Isotypes of serum Abs against SARS-CoV-2 spike produced by hospitalized and ambulatory

234 **patients.** To understand the Fc properties of Abs raised against SARS-CoV-2 in patients presenting with

235	distinct COVID-19 severity, we examined spike-specific Ig isotypes in a subset of hospitalized (n=6) vs.
236	ambulatory cases (n=14) in which each hospitalized patient was matched to two or three ambulatory
237	patients based on sex, time post-infection (early: <25 days vs. late: >130 days post-infection),
238	comorbidities (none vs. at least one), and spike-specific total Ig levels (< half a log10) (Table 2). Four
239	COVID-19-negative plasma specimens were included to establish background levels. All the patients had
240	IgM, IgG1, IgG3 and IgA1 spike-specific Abs. The levels of these isotypes and subtypes did not differ
241	between the hospitalized and ambulatory groups (Fig 3). Similar results were observed with Ig isotypes
242	against RBD (Supplemental Fig 2). Some patients also mounted IgG2 and IgG4 Ab responses. The levels
243	of these IgG subtypes were relatively low, and no difference was apparent between matched hospitalized
244	and ambulatory patients. These data demonstrate that hospitalized and ambulatory patients display a
245	comparable array of serum Ig isotypes against SARS-CoV-2 spike and RBD.
246	
246 247	Fab-mediated neutralization and Fc-mediated activities of SARS-CoV-2-specific Abs among
246 247 248	Fab-mediated neutralization and Fc-mediated activities of SARS-CoV-2-specific Abs among matched hospitalized and ambulatory VA patients. The matched set of hospitalized and ambulatory
246247248249	Fab-mediated neutralization and Fc-mediated activities of SARS-CoV-2-specific Abs among matched hospitalized and ambulatory VA patients. The matched set of hospitalized and ambulatory specimens was next tested for Ab activities against SARS-CoV-2. In addition to Fab-mediated
 246 247 248 249 250 	Fab-mediated neutralization and Fc-mediated activities of SARS-CoV-2-specific Abs among matched hospitalized and ambulatory VA patients. The matched set of hospitalized and ambulatory specimens was next tested for Ab activities against SARS-CoV-2. In addition to Fab-mediated neutralization, we examined Fc-mediates activities: spike-specific ADCP and spike- or RBD-complement
 246 247 248 249 250 251 	Fab-mediated neutralization and Fc-mediated activities of SARS-CoV-2-specific Abs among matched hospitalized and ambulatory VA patients. The matched set of hospitalized and ambulatory specimens was next tested for Ab activities against SARS-CoV-2. In addition to Fab-mediated neutralization, we examined Fc-mediates activities: spike-specific ADCP and spike- or RBD-complement binding (C1q and C3d) (Fig 4 and Supplemental Fig 3). Similar to the neutralization data shown in Fig 2
 246 247 248 249 250 251 252 	Fab-mediated neutralization and Fc-mediated activities of SARS-CoV-2-specific Abs among matched hospitalized and ambulatory VA patients. The matched set of hospitalized and ambulatory specimens was next tested for Ab activities against SARS-CoV-2. In addition to Fab-mediated neutralization, we examined Fc-mediates activities: spike-specific ADCP and spike- or RBD-complement binding (C1q and C3d) (Fig 4 and Supplemental Fig 3). Similar to the neutralization data shown in Fig 2 for all samples, neutralization levels between matched hospitalized (median IC ₅₀ of 175) and ambulatory
 246 247 248 249 250 251 252 253 	Fab-mediated neutralization and Fc-mediated activities of SARS-CoV-2-specific Abs among matched hospitalized and ambulatory VA patients. The matched set of hospitalized and ambulatory specimens was next tested for Ab activities against SARS-CoV-2. In addition to Fab-mediated neutralization, we examined Fc-mediates activities: spike-specific ADCP and spike- or RBD-complement binding (C1q and C3d) (Fig 4 and Supplemental Fig 3). Similar to the neutralization data shown in Fig 2 for all samples, neutralization levels between matched hospitalized (median IC ₅₀ of 175) and ambulatory (median IC ₅₀ of 142) specimens were not different (Fig 4a). While certain hospitalized patients displayed
 246 247 248 249 250 251 252 253 254 	Fab-mediated neutralization and Fc-mediated activities of SARS-CoV-2-specific Abs among matched hospitalized and ambulatory VA patients. The matched set of hospitalized and ambulatory specimens was next tested for Ab activities against SARS-CoV-2. In addition to Fab-mediated neutralization, we examined Fc-mediates activities: spike-specific ADCP and spike- or RBD-complement binding (C1q and C3d) (Fig 4 and Supplemental Fig 3). Similar to the neutralization data shown in Fig 2 for all samples, neutralization levels between matched hospitalized (median IC ₅₀ of 175) and ambulatory (median IC ₅₀ of 142) specimens were not different (Fig 4a). While certain hospitalized patients displayed higher IC ₅₀ than their matched ambulatory counterparts, some others had lower IC ₅₀ values. Fc-mediated
 246 247 248 249 250 251 252 253 254 255 	Fab-mediated neutralization and Fc-mediated activities of SARS-CoV-2-specific Abs among matched hospitalized and ambulatory VA patients. The matched set of hospitalized and ambulatory specimens was next tested for Ab activities against SARS-CoV-2. In addition to Fab-mediated neutralization, we examined Fc-mediates activities: spike-specific ADCP and spike- or RBD-complement binding (C1q and C3d) (Fig 4 and Supplemental Fig 3). Similar to the neutralization data shown in Fig 2 for all samples, neutralization levels between matched hospitalized (median IC ₅₀ of 175) and ambulatory (median IC ₅₀ of 142) specimens were not different (Fig 4a). While certain hospitalized patients displayed higher IC ₅₀ than their matched ambulatory counterparts, some others had lower IC ₅₀ values. Fc-mediated spike-specific ADCP also showed no apparent trend, and the levels were indistinguishable between
 246 247 248 249 250 251 252 253 254 255 256 	Fab-mediated neutralization and Fc-mediated activities of SARS-CoV-2-specific Abs among matched hospitalized and ambulatory VA patients. The matched set of hospitalized and ambulatory specimens was next tested for Ab activities against SARS-CoV-2. In addition to Fab-mediated neutralization, we examined Fc-mediates activities: spike-specific ADCP and spike- or RBD-complement binding (C1q and C3d) (Fig 4 and Supplemental Fig 3). Similar to the neutralization data shown in Fig 2 for all samples, neutralization levels between matched hospitalized (median IC ₅₀ of 175) and ambulatory (median IC ₅₀ of 142) specimens were not different (Fig 4a). While certain hospitalized patients displayed higher IC ₅₀ than their matched ambulatory counterparts, some others had lower IC ₅₀ values. Fc-mediated spike-specific ADCP also showed no apparent trend, and the levels were indistinguishable between hospitalized and ambulatory groups (median AUC of 518 and 485, respectively) (Fig 4b). When

258 binding was found to be similar for both groups, and the C3d deposition levels also did not differ (Fig 4c-

259 d and Supplemental Fig 3).

260 Correlation matrix was compiled from both binding and functional Ab data of the hospitalized and 261 matched ambulatory groups. A remarkable difference was noted: in the hospitalized group, a strong 262 positive correlation was observed between the levels of S2-specific Ig and the other Ab parameters tested, 263 whereas the correlation was weaker or absent in the ambulatory group (Fig 5a-b). Indeed, in the 264 ambulatory group, poor correlation was apparent between the anti-S2 Ig levels and the Ig levels against 265 the entire spike protein, S1, or RBD (Fig 5b). These results indicate a discordance of Ab responses against 266 the relatively conserved S2 subunit vs. the rest of spike regions in the ambulatory cases but not the 267 hospitalized cases.

268

282

269 **Differences in cytokines responses among hospitalized and ambulatory patients.** In addition to 270 evaluating the Ab responses, we examined the cytokines profile of these convalescent COVID-19 patients. 271 Fifty-two COVID-19-convalescent patients and 28 COVID-19 negative sera were tested for 48 cytokines 272 and chemokines, many of which participate in induction and modulation of inflammatory responses (Figs 273 6 and 7. Supplemental Figs 4-7). Twelve cytokines/chemokines were found to be significantly different 274 between COVID-19-positive and negative groups (Fig 6a, Supplemental Fig 4). MDC and RANTES 275 were significantly higher in COVID-19 convalescent sera than negative controls, while the remaining 10 276 were lower in COVID-19 convalescent sera, with sCD40L and IL-17E/IL-25 displaying p values of 277 <0.0001. Linear regression analysis of these 12 cytokines showed that the cytokine levels did not change 278 significantly up to 250 days after COVID-19 disease onset (Supplemental Fig 5), except for IL-15 and 279 M-CSF which declined over time (slope=-0.001 and -0.002, and p=0.02 and 0.007). 280 We subsequently compared COVID-19 patients with different disease severity and asked whether the 281 cytokines/chemokine responses were elevated in hospitalized patients compared to ambulatory patients

(Supplemental Figs 6b and 6c, and Fig 7). The median modified Z scores showed an overall higher

283	response in the hospitalized vs. ambulatory patients (p=0.03), with higher median values observed in a
284	constellation of cytokines/chemokines (e.g. IL-4, IL-7, IL-8, IL-13, IL-17A, IL-17E/IL-25, IL-18, IL-22,
285	IL-27, MCP-3, M-CSF, MDC, MIG/CXCL9, MIP-1α, MIP-1β, PDGF-AA, and TNF-β) (Supplemental
286	Fig 6b). Correlation matrices of these cytokine/chemokine data further supported the notion of a stronger
287	coordination of cytokine/chemokine alterations among the hospitalized patients as compared to the
288	ambulatory patients whose correlation matrix was similar to that of the negative control (Supplemental
289	Fig 7).
290	Comparison was also performed on individual cytokines or chemokines, and two cytokines were found to
291	be significantly higher in hospitalized vs. ambulatory patients: IL-4 and IL-27 (Fig 6b). These were
292	distinct from the 12 found to differ between COVID-19 positive and negative groups, and their levels did
293	not significantly decline over 250 days post disease onset (slope= -0.0001 and -0.0005 , and p >0.05,
294	Supplemental Fig 5). When we evaluated the subset of matched severe and mild specimens, only IL-27
295	remained significantly higher in hospitalized vs. ambulatory patients with p value of 0.03 (Fig 6c).
296	Therefore, the higher IL-27 levels between the hospitalized vs. ambulatory groups were evident in the
297	plots of all COVID-19 patients (Fig 7a) and in the matched subset (Fig 7b). For comparison, two other
298	cytokines were also plotted (Fig 7c-f). IL-4 was higher in sera of hospitalized vs. all ambulatory patients
299	(Fig 7c) but showed inconsistent patterns in the matched subsets (Fig 7d). FGF-2, on the other hand, was
300	comparable in hospitalized patients and all or matched ambulatory patients (Fig 7e, f). Notably, the IL-27
301	levels correlated with IL-1 α , IL-3, IL-6 and TNF- α (Spearman r=0.61–0.75 and p=0.01–0.03) in the
302	hospitalized patients, but not in the ambulatory patients (Supplemental Fig 7).
303	

304 Discussion

305 This study examined serum Ab and cytokine/chemokine responses in SARS-CoV-2-infected patients with 306 demographic risk factors for developing severe COVID-19, which included older age, male sex, and

13

307 Black/Hispanic racial or ethnic background. Most patients (81%), however, had mild disease requiring no 308 hospitalization, and only ten were hospitalized. Comparison of the hospitalized vs. ambulatory patients 309 within the cohort revealed comparable virus-specific Ab responses in terms of binding levels, 310 neutralization titers, and Fc-mediated activities of ADCP and complement deposition. However, the S2-311 specific Ig responses were distinguishing in that anti-S2 Ab levels tended to increase in hospitalized 312 patients and decrease in ambulatory patients over time, and correlated with all other Ab parameters tested 313 more strongly among hospitalized patients than ambulatory patients. Furthermore, the overall cytokine 314 responses in sera, which were collected from four days to >7 months post-disease onset, were elevated in 315 the hospitalized vs. ambulatory patients. The IL-4 and IL-27 levels were notably higher in the hospitalized 316 group and showed no apparent decline over the >7-month period. The greater levels of IL-27, but not IL-317 4, were maintained when the hospitalized patients were matched to subsets of ambulatory patients by 318 absence or presence of comorbidities, early or late sample collection time, and spike-specific total Ig 319 levels. Nonetheless, the importance of S2-specific Abs and IL-27 in contributing to and/or resulting from 320 severe COVID-19 remains unclear and warrants further investigation. 321 IL-27 is a heterodimeric IL-12 family cytokine, consisting of IL-12p35-related p28 and Epstein-Barr 322 virus-induced 3 (EBI3) proteins (40). Together with IL-12, IL-27 is an initiator of Th1 polarization of 323 CD4+ cells (41,42). IL-27 also promotes IFN- γ production by CD8+ T cells and NKT cells (43). Myeloid 324 cell populations, including macrophages, inflammatory monocytes, microglia, and dendritic cells are the 325 main sources of IL-27, which can be elicited by a range of microbial and immune stimuli (44). IL-27 326 signaling in turn can induce the release of pro-inflammatory cytokines such as IL-1, TNF- α , IL-18, and 327 IL-12 (45,46). Indeed, our data showed that IL-27 levels correlated with those of IL-1 α and TNF- α and 328 that, with IL-27, IL-18 was elevated in hospitalized vs. ambulatory cases albeit without statistical 329 significance. In a study looking at cytokine and leukocyte profile of 44 SARS-CoV-2-infected patients 330 that were separated in two groups based on age (> or <60 years old), IL-27, together with CXCL8, IL-10,

331 IL-15 and TNF- α , was associated to older age, longer hospitalization, and more severe COVID-19 (29). In 332 contrast, in a Singapore cohort, no difference was observed in IL-4 and IL-27 levels between symptomatic 333 and asymptomatic patients; rather, higher levels of MCP-1 and PDGF-BB were detected in patients with 334 persistent symptoms vs. symptom-free patients (47). Beyond COVID-19, the levels of IL-27 were found 335 to increase in patients with pulmonary inflammatory diseases including tuberculosis, asthma, influenza, 336 acute lung injury, lung cancer, chronic obstructive pulmonary disease, acute lung injury, acute respiratory 337 distress syndrome, and community-acquired pneumonia (48–53), indicating that an elevated IL-27 level is 338 likely a common response to lung infections and injuries.

339 In contrast to Th1-promoting IL-27, IL-4 is a cytokine that induces Th2 differentiation. Upon activation

by IL-4, Th2 cells subsequently produce additional IL-4 in a positive feedback loop. IL-4 is produced

341 primarily by mast cells, Th2 cells, eosinophils and basophils (54). IL-4, along with other Th2 cytokines, is

involved in the airway inflammation observed in the lungs of patients with allergic asthma (55). In our

343 COVID-19 cohort, IL-4 levels were higher when the hospitalized cases were compared with all

ambulatory patients but not with matched ambulatory patients. Conflicting results also have been

345 published regarding IL-4, which was either associated with severe COVID-19 (19), or was thought to be

beneficial for the recovery of COVID-19 patients (56).

A constellation of elevated cytokines has been associated with severe cases of COVID-19. Here we

348 observed higher median values for several cytokines in hospitalized vs. ambulatory groups, although only

349 IL-27 was significantly elevated in hospitalized patients as compared to all and matched ambulatory

350 patients. Interestingly, in the hospitalized patients but not in the ambulatory patients, the levels of IL-27

- 351 correlated with those of IL-1α, IL-3, IL-6 and TNF-α, which were previously reported to be elevated and
- 352 correlated with severe COVID-19 (28,29,57,58). A study looking at serum IL-6, IL-8 and TNF-α at the

time of hospitalization also found that they were strong and independent predictors of patient survival in a

354 cohort of hospitalized patients (57). Yet, another study measuring IL-6 and IL-18 serum levels found IL-

355 18 to correlate with other inflammatory markers and reflect disease severity (59). And a different study
356 looking at 48 cytokines, chemokines, and growth factors showed significantly higher IL-12 levels in the
357 asymptomatic and mild disease groups than in the moderate and severe disease groups, while IL-4 levels
358 were comparable and IL-27 was not examined (60). Nonetheless, these studies did not separate the
359 individuals based on associated comorbidities, age, or racial/ethnic groups.

360 Limited information is available about cytokine responses among US minority groups, in particular

361 African Americans and Hispanics who have higher rates of SARS-COV-2 infection, hospitalization, and

death (30,61,62). African Americans are also more likely to have diabetes, hypertension, obesity, asthma,

and heart disease, all of which are comorbidities associated with severe COVID-19. Moreover, little is

364 known about cytokine levels in this population and in the context of associated comorbidities. The

365 COVID-19-associated hospitalization rates are also higher among males than females (5.1 vs. 4.1 per

366 100,000) (61). Indeed, markers of brain and endothelial injury and inflammation were shown to be sex

367 specifically regulated in SARS-CoV-2 infection (63). Nonetheless, scant information is available

368 regarding the differences/similarities in cytokine levels between males and females, even though sex

369 differences are likely to impact immune responses to SARS-CoV-2, as seen against other viruses, for

370 examples, sex hormone-regulated pDC responses and sex differences in cytokine and chemokine

371 production and neutrophil recruitment during influenza virus infection (64).

375

In terms of Ab responses, the levels of anti-SARS-CoV-2 Abs, in particular IgA, and neutralization
activities have been positively associated with COVID-19 severity (8–10). A longitudinal study of Italian

374 patients presenting a wide range of clinical manifestations identified anti-S1 IgA as an indicator of

COVID-19 severity (65). We performed Ig isotyping with the entire spike protein, precluding assessment

of Ig isotypes against S1 and S2 subunits. In another study, faster induction of S2-reactive IgG during the

377 first week of infection, along with IgG cross-reactivity with the common human beta coronaviruses (β -

378 hCoVs), correlated with COVID-19 severity, implicating a biased early response toward S2 epitopes

379 cross-reactive with hCoVs (66). Comparison of spike proteins from SARS-CoV-2 (WA1) and hCoV 380 strains shows varying levels of amino acid conservation across different spike regions. S1 and RBD 381 exhibit only 25% to 30% identity, while S2 has higher percent identity: 41% to 42% with β -hCoVs (OC43) 382 and HKU1), and 34% with α-hCoVs (229E and NL63). In our study, a distinguishable feature of Ab 383 responses was the stronger concordance of Ig levels against S2 with anti-S1 Ig, anti-RBD Ig, and the other 384 tested Ab parameters in the severe vs. ambulatory cases. These results suggest that the Ab responses to the 385 S1 and S2 regions of spike were upregulated synchronously in the patients who went on to have severe 386 COVID-19, but not in patients with mild cases. The S2-specific Ig responses were relatively low in both 387 groups but tended to decline over time and disconnect from those of S1 in the ambulatory group. The S2 388 epitopes targeted by Abs from severe vs. mild cases in our study have not been determined, but Abs 389 against certain sites in the more conserved S2 subunit may play a role in preventing or promoting 390 progression to severe COVID-19. Neutralizing mAbs against S2 have been reported, such as 3A3 specific 391 for a conserved epitope in the hinge region between the heptad repeat-1 helix and the central helix (67) 392 and B1 recognizing the beta-hairpin region (68), although the prevalence of these Abs in COVID-19 393 patients is unknown. Garrido et al. demonstrated a correlation of IgG targeting different immunodominant 394 conserved S2 regions with COVID-19 severity: Abs against heptad repeat-2 and S2' fusion peptide 395 correlated with milder and more severe disease, respectively (69); the functional aspects of these anti-S2 396 Abs are yet to be evaluated. Further studies also are warranted to focus on the activities of pre-existing and 397 SARS-CoV-2-induced S2-specific Abs, including neutralization, Fab affinity, Fc glycosylation, and 398 affinity for Fc receptors and complement, in patients with different disease severity and after COVID-19 399 vaccination.

Fc-mediated Ab functions also have been associated with COVID-19 severity. Abs-mediated FcγRIIa and
FcγRIIIa activation positively correlated with symptom severity among ambulatory New York patients at
1-2 months post-disease onset (69). Additionally, IgG Fc glycome composition was shown to predict

...

403	disease severity, with patients with a poor outcome having, at diagnosis, IgG deficient in galactosylation
404	and sialylation and more bis-GlcNAc structures (13). Since the Fc glycan composition influences Fc-
405	mediated functions, further investigation may reveal distinct Fc activities. We previously observed higher
406	complement-binding potency of SARS-CoV-2 spike-specific Abs elicited by vaccination vs. infection
407	(35). In this study, comparable complement binding potencies were seen in spike-specific Abs from
408	hospitalized vs. ambulatory COVID-19 patients. ADCP capacity was also similar, while other Fc activities
409	such as antibody-dependent cellular cytotoxicity and affinity for the different Fcy receptors have not been
410	studied.

. .

411 The study was subject to additional limitations. The samples sizes were small, especially for the 412 hospitalized patients, and this group included only survivors. Future study with larger sample sizes is 413 needed to differentiate hospitalized patients requiring different levels of care and interventions and to 414 match patient groups by race/ethic groups and specific comorbidities. In addition, all samples were 415 collected from patients during the first wave of infection in New York City in March-December 2020, 416 when the initial SARS-CoV-2 variant was predominant and no vaccine or antiviral therapeutic 417 intervention were available. It is unknown if the data presented herein can be extrapolated directly to 418 responses against Delta, Omicron, and other variants emerging in the future. Vaccines and therapeutics 419 now widely available would also impact Ab and cytokine/chemokine responses to infection. The antiviral 420 functional assays were also limited to neutralization, ADCP, and complement binding, and to the 421 evaluation of the original SARS-CoV-2 variant using recombinant protein or pseudovirus. Lastly, our 422 study is primarily cross-sectional with samples from different subjects over a wide range of time points 423 post-infection. Although minimal changes were apparent in the levels of antibodies and cytokines during 424 the observation period, the individual responses at the early and late time points may differ and were not 425 studied herein. The longitudinal samples tested for the initial nucleoprotein-IgG study were unavailable 426 for the subsequent experiments.

427	In summary, among the older and mostly male VA patients studied, SARS-CoV-2-specific Ab levels and
428	functional activities did not distinguish hospitalized and ambulatory COVID-19 cases. However, a
429	discordant S2-specific Ab response was noted among the ambulatory patients. Moreover, higher levels of
430	cytokines, notably IL-4 and IL-27, were induced and maintained in hospitalized vs. ambulatory cases.
431	These data offer a pathway to pursue for a better understanding of the immune mechanisms that play a
432	role in protection against vs. progression to severe COVID-19.
433	
434	Contributors
435	J.K., S.Z-P., C.U., and C.E.H. wrote and edited the manuscript. J.K., C.E.H., and S.Z-P. designed the
436	experiments. J.K. and G.S.L. performed the experiments and collected the data. J.K., G.S.L, A.N., C.U.
437	and C.E.H. analyzed the data. K.Y.O., F.A., and B.L. provided protocols, antigens, cells, and pseudovirus
438	stocks. V.S. and the PARIS study group provided banked human samples, J.C.B., R.E-G., and J.J.I.
439	obtained specimens. All authors read and approved the final manuscript.
440	
441 442 443 444 445	PARIS Study Team: Angela A. Amoako, Dalles Andre, Mahmoud H. Awawda, Katherine F. Beach, Maria C. Bermúdez-González, Rachel L Chernet, Emily D. Ferreri, Daniel L. Floda, Joshua Hamburger, Giulio Kleiner, Neko Lyttle, Wanni A Mendez, Lubbertus CF Mulder, Ismail Nabeel, Kayla Russo, Ashley Beathrese T. Salimbangon, Miti Saksena, Levy A. Sominsky, Ania Wajnberg.

446 **Declaration of Interests**

447 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2

448 serological assays (U.S. Provisional Application Number 63/051,858, which list Viviana Simon as co-

449 inventor.

450

451 Source of funding statements

464	Acknowledgments
463	
462	Final de-identified data sets underlying this publication will be shared upon written request.
461	Data sharing
460	
459	contract 75N93019C00051 (PI: Dr. Krammer).
458	The PARIS cohort is funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC)
457	AI139290] to C.E.H., [grants R01 AI123449, R21 AI1498033] to B.L, [grant R01 AI140909] to C.U.
456	[Research Career Scientist Award 1IK6BX004607] (to C.E.H.); the National Institutes of Health [grant
455	(to B.L.), the Department of Veterans Affairs [Merit Review Grant I01BX005794] (to C.E.H.) and
454	Coleman estate for endowing the Ward-Coleman Chairs at the Icahn School of Medicine at Mount Sinai
453	Mount Sinai Department of Medicine (to S.Z-P., C.E.H.); the Department of Microbiology and the Ward-
452	This work was supported in part by the Department of Medicine of the Icann School of Medicine at

- 465 We thank Dr. Florian Krammer for providing spike and RBD antigens, and all the study participants for
- their contribution to the research. We would like to thank the expertise and assistance of Dr. Christopher
- 467 Bare and the Dean's Flow Cytometry CORE at Mount Sinai.
- 468

469 **References**

- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease
 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for
 Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239–42.
- 473 2. Yang R, Gui X, Xiong Y. Comparison of Clinical Characteristics of Patients with Asymptomatic
 474 vs Symptomatic Coronavirus Disease 2019 in Wuhan, China. JAMA Netw Open. 2020 May
 475 27 2(5) 2010102
- 475 27;3(5):e2010182.
- Aslan A, Aslan C, Zolbanin NM, Jafari R. Acute respiratory distress syndrome in COVID-19:
 possible mechanisms and therapeutic management. Pneumonia. 2021 Dec 6;13:14.
- 478
 47. Chow N, Fleming-Dutra K, Gierke R, Hall A, Hughes M, Pilishvili T, et al. Preliminary Estimates
 479 of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease

480 2019 — United States, February 12–March 28, 2020. Morb Mortal Wkly Rep. 2020 Apr 3;69(13):382–6. 481 5. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control 482 and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases 483 (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi Zhonghua Liuxingbingxue Zazhi. 2020 Feb 484 10;41(2):145–51. 485 Sharma G, Volgman AS, Michos ED. Sex Differences in Mortality From COVID-19 Pandemic: 6. 486 Are Men Vulnerable and Women Protected? JACC Case Rep. 2020 Jul 15:2(9):1407–10. 487 7. COVID-19, Equity and Men's Health | International Journal of Mens Social and Community 488 Health. 2020 Jul 6 [cited 2022 Mar 29]: Available from: 489 http://ijmsch.com/index.php/IJMSCH/article/view/42 490 8. Chvatal-Medina M, Mendez-Cortina Y, Patiño PJ, Velilla PA, Rugeles MT. Antibody Responses 491 in COVID-19: A Review. Front Immunol. 2021 Apr 15;12:633184. 492 Ravichandran S, Lee Y, Grubbs G, Coyle EM, Klenow L, Akasaka O, et al. Longitudinal antibody 9. 493 repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease 494 severity and resolution. Sci Adv. 2021 Mar;7(10):eabf2467. 495 Tang J, Ravichandran S, Lee Y, Grubbs G, Coyle EM, Klenow L, et al. Antibody affinity 10. 496 maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients. Nat 497 Commun. 2021 Feb 22;12(1):1221. 498 Yang HS, Costa V, Racine-Brzostek SE, Acker KP, Yee J, Chen Z, et al. Association of Age With 11. 499 SARS-CoV-2 Antibody Response. JAMA Netw Open. 2021 Mar 22;4(3):e214302. 500 Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in 12. 501 immune responses that underlie COVID-19 disease outcomes. Nature. 2020 Aug 26;1–9. 502 Vicente MM, Alves I, Gaifem J, Rodrigues CS, Fernandes Â, Dias AM, et al. Altered IgG 13. 503 glycosylation at COVID-19 diagnosis predicts disease severity. Eur J Immunol [Internet]. [cited 2022 Apr 504 4];n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/eji.202149491 Lu-Culligan A, Chavan AR, Vijayakumar P, Irshaid L, Courchaine EM, Milano KM, et al. 505 14. 506 Maternal respiratory SARS-CoV-2 infection in pregnancy is associated with a robust inflammatory response at the maternal-fetal interface. Med N Y N. 2021 May 14;2(5):591-610.e10. 507 508 Arunachalam PS, Wimmers F, Mok CKP, Perera RAPM, Scott M, Hagan T, et al. Systems 15. 509 biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science. 2020 510 Sep 4:369(6508):1210-20. 511 Rizzi M, Costanzo M, Tonello S, Matino E, Casciaro FG, Croce A, et al. Prognostic Markers in 16. 512 Hospitalized COVID-19 Patients: The Role of IP-10 and C-Reactive Protein. Dis Markers. 513 2022;2022:3528312. 514 Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, et al. Viral and host factors related to the clinical 17. 515 outcome of COVID-19. Nature. 2020 Jul;583(7816):437-40. 516 Jing X, Xu M, Song D, Yue T, Wang Y, Zhang P, et al. Association between inflammatory 18. 517 cytokines and anti-SARS-CoV-2 antibodies in hospitalized patients with COVID-19. Immun Ageing A. 518 2022 Mar 5:19(1):12. Hu H, Pan H, Li R, He K, Zhang H, Liu L. Increased Circulating Cytokines Have a Role in 519 19. 520 COVID-19 Severity and Death With a More Pronounced Effect in Males: A Systematic Review and Meta-521 Analysis. Front Pharmacol. 2022;13:802228. 522 Walter LO, Cardoso CC, Santos-Pirath ÍM, Costa HZ, Gartner R, Werle I, et al. The relationship 20. 523 between peripheral immune response and disease severity in SARS-CoV-2-infected subjects: A cross-524 sectional study. Immunology. 2022 Apr;165(4):481–96. 525 Smieszek SP, Polymeropoulos VM, Polymeropoulos CM, Przychodzen BP, Birznieks G, 21. 526 Polymeropoulos MH. Elevated plasma levels of CXCL16 in severe COVID-19 patients. Cytokine. 2022 Apr;152:155810. 527

Meffre E, Iwasaki A. Interferon deficiency can lead to severe COVID. Nature. 2020 528 22. 529 Nov;587(7834):374-6. 530 Zhang O, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN 23. 531 immunity in patients with life-threatening COVID-19. Science. 2020 Oct 23;370(6515):eabd4570. 532 Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies 24. 533 against type I IFNs in patients with life-threatening COVID-19. Science. 2020 Oct 534 23;370(6515):eabd4585. 535 25. Ruetsch C, Brglez V, Crémoni M, Zorzi K, Fernandez C, Boyer-Suavet S, et al. Functional 536 Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients. Front Med. 537 2020;7:603961. 538 26. Dyavar SR, Singh R, Emani R, Pawar GP, Chaudhari VD, Podany AT, et al. Role of toll-like 539 receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-540 CoV2 infection and potential therapeutic options. Biomed Pharmacother. 2021 Sep;141:111794. 541 Ma A, Zhang L, Ye X, Chen J, Yu J, Zhuang L, et al. High Levels of Circulating IL-8 and Soluble 27. 542 IL-2R Are Associated With Prolonged Illness in Patients With Severe COVID-19. Front Immunol. 543 2021;12:626235. 544 28. Ling L, Chen Z, Lui G, Wong CK, Wong WT, Ng RWY, et al. Longitudinal Cytokine Profile in 545 Patients With Mild to Critical COVID-19. Front Immunol. 2021 Dec 6;12:763292. 546 Angioni R, Sánchez-Rodríguez R, Munari F, Bertoldi N, Arcidiacono D, Cavinato S, et al. Age-29. 547 severity matched cytokine profiling reveals specific signatures in Covid-19 patients. Cell Death Dis. 2020 548 Nov 6:11(11):957. 549 Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Skanderson M, et al. Patterns of COVID-30. 550 19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. 551 PLoS Med. 2020 Sep 22;17(9):e1003379. 552 Haralambieva IH, Salk HM, Lambert ND, Ovsyannikova IG, Kennedy RB, Warner ND, et al. 31. 553 Associations between race, sex and immune response variations to rubella vaccination in two independent 554 cohorts. Vaccine. 2014 Apr 7;32(17):1946-53. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A 555 32. 556 serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020 May 12;1-4. 557 33. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al. SARS-558 CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and 559 Test Setup. Curr Protoc Microbiol. 2020;57(1):e100. Weiss S, Klingler J, Hioe C, Amanat F, Baine I, Kojic EM, et al. A High Through-put Assay for 560 34. 561 Circulating Antibodies Directed against the S Protein of Severe Acute Respiratory Syndrome Corona virus 562 2. medRxiv. 2020 Apr 17;2020.04.14.20059501. 563 35. Klingler J, Lambert GS, Itri V, Liu S, Bandres JC, Envindah-Asonye G, et al. Detection of 564 Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected 565 Individuals. Front Immunol. 2021;12:759688. Klingler J, Weiss S, Itri V, Liu X, Oguntuyo KY, Stevens C, et al. Role of IgM and IgA 566 36. 567 Antibodies in the Neutralization of SARS-CoV-2. J Infect Dis. 2020 Dec 24; 568 Oguntuyo KY, Stevens CS, Hung CT, Ikegame S, Acklin JA, Kowdle SS, et al. Quantifying 37. 569 absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera. medRxiv. 2020 Aug 15;2020.08.13.20157222. 570 571 Ikegame S, Siddiquey MNA, Hung CT, Haas G, Brambilla L, Oguntuyo KY, et al. Neutralizing 38. 572 activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nat Commun. 2021 Jul 26;12:4598. 573 Balasubramanian P, Williams C, Shapiro MB, Sinangil F, Higgins K, Nádas A, et al. Functional 39. 574 Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials. 575 Sci Rep. 2018 Jan 11;8(1):542.

576 577	40. Dokmeci E, Xu L, Robinson E, Golubets K, Bottomly K, Herrick CA. EBI3 deficiency leads to diminiched T helper ture 1 and increased T helper ture 2 mediated airway inflammation. Immunology			
570	2011 Apr: 122(4):550 66			
570	2011 Api,152(4).559-00. A1 Kestelein RA Hunter CA Cue DI Discovery and biology of IL-23 and IL-27: related but			
580	functionally distinct regulators of inflammation Annu Pay Immunol 2007:25:221 42			
581	$A_2 = O$ waki T. Asakawa M. Morishima N. Hata K. Eukai E. Matsui M. at al. A role for II. 27 in early			
587	42. Owaki T, Asakawa W, Monshinia N, Hata K, Fukai F, Matsur W, et al. A fold for http://litearry			
582	A2 Carl IW Bai XE II 27: Its Poles in the Induction and Inhibition of Inflammation. Int I Clin Exp.			
58/	Pathol 2008 Jap 1.1(2):117-23			
585	AA = X Voshida H Hunter CA. The immunobiology of interleukin-27 Annu Rev Immunol. 2015:33:417-			
586	-43			
587	45. Wittmann M. Zeitvogel I. Wang D. Werfel T. II -27 is expressed in chronic human eczematous			
588	skin lesions and stimulates human keratinocytes. I Allergy Clin Immunol 2009 Jul:124(1):81–9			
589	46 Artis D Villarino A Silverman M He W Thornton FM Mu S et al The II -27 recentor (WSX-1)			
590	is an inhibitor of innate and adaptive elements of type 2 immunity. I Immunol 2004 Nov 1:173(9):5626_			
591	34.			
592	47. Ong SWX, Fong SW, Young BE, Chan YH, Lee B, Amrun SN, et al. Persistent Symptoms and			
593	Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients.			
594	Open Forum Infect Dis. 2021 Jun:8(6):ofab156.			
595	48. Xu Z. Wang XM. Cao P. Zhang C. Feng CM. Zheng L. et al. Serum IL-27 predicts the severity			
596	and prognosis in patients with community-acquired pneumonia: a prospective cohort study. Int J Med Sci.			
597	2022 Jan 1;19(1):74–81.			
598	49. Xu F, Liu Q, Lin S, Shen N, Yin Y, Cao J. IL-27 is elevated in acute lung injury and mediates			
599	inflammation. J Clin Immunol. 2013 Oct;33(7):1257–68.			
600	50. Cao J, Zhang L, Li D, Xu F, Huang S, Xiang Y, et al. IL-27 is elevated in patients with COPD and			
601	patients with pulmonary TB and induces human bronchial epithelial cells to produce CXCL10. Chest.			
602	2012 Jan;141(1):121–30.			
603	51. Su Y, Yao H, Wang H, Xu F, Li D, Li D, et al. IL-27 enhances innate immunity of human			
604	pulmonary fibroblasts and epithelial cells through upregulation of TLR4 expression. Am J Physiol Lung			
605	Cell Mol Physiol. 2016 Jan 15;310(2):L133-141.			
606	52. Kopiński P, Wandtke T, Dyczek A, Wędrowska E, Roży A, Senderek T, et al. Increased levels of			
607	interleukin 27 in patients with early clinical stages of non-small cell lung cancer. Pol Arch Intern Med.			
608	2018 Feb 28;128(2):105–14.			
609	53. Babadi AS, Kiani A, Mortaz E, Taghavi K, Khosravi A, Marjani M, et al. Serum Interleukin-27			
610	Level in Different Clinical Stages of Lung Cancer. Open Access Maced J Med Sci. 2019 Jan 15;7(1):45–			
611	9.			
612	54. Gadani SP, Cronk JC, Norris GT, Kipnis J. Interleukin-4: A Cytokine to Remember. J Immunol			
613	Baltim Md 1950. 2012 Nov 1;189(9):4213–9.			
614	55. Gour N, Wills-Karp M. IL-4 and IL-13 Signaling in Allergic Airway Disease. Cytokine. 2015			
615	Sep;75(1):68–78.			
616	56. Wen W, Su W, Tang H, Le W, Zhang X, Zheng Y, et al. Immune cell profiling of COVID-19			
617	patients in the recovery stage by single-cell sequencing. Cell Discov. 2020 May 4;6:31.			
618	57. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An			
619	inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020 Aug 24;1–8.			
620	58. Benard A, Jacobsen A, Brunner M, Krautz C, Klösch B, Swierzy I, et al. Interleukin-3 is a			
621	predictive marker for severity and outcome during SARS-CoV-2 infections. Nat Commun. 2021 Feb			
622	18;12(1):1112.			
623	59. Satiş H, Ozger HS, Aysert Yıldız P, Hızel K, Gulbahar O, Erbaş G, et al. Prognostic value of			

- interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19. 624 625 Cytokine. 2021 Jan;137:155302. Tian LH, Furukawa K, Nagano T, Kiriu T, Nishimura M, Arii J, et al. Early Differences in 626 60. Cytokine Production by Severity of Coronavirus Disease 2019. J Infect Dis. 2021 Jan 7;223(7):1145–9. 627 628 61. Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, et al. Hospitalization Rates 629 and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -630 COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-631 64. 632 62. Alcendor DJ. Racial Disparities-Associated COVID-19 Mortality among Minority Populations in 633 the US. J Clin Med. 2020 Jul 30;9(8):2442. 634 63. Savarraj J, Park E, Copo G, Hinds S, Morales D, Ahnstedt H, et al. Markers of brain and 635 endothelial Injury and inflammation are acutely and sex specifically regulated in SARS-CoV-2 infection. In: medRxiv. 2021. 636 Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex 637 64. 638 impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020 Jul;20(7):442-7. 639 Siracusano G, Brombin C, Pastori C, Cugnata F, Noviello M, Tassi E, et al. Profiling Antibody 65. 640 Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 641 Infection. Front Immunol [Internet]. 2021 [cited 2022 Jun 8];12. Available from: 642 https://www.frontiersin.org/article/10.3389/fimmu.2021.772239 643 Wang J, Li D, Cameron A, Zhou Q, Wiltse A, Nayak J, et al. IgG Against Human Betacoronavirus 66. 644 Spike Proteins Correlates With SARS-CoV-2 Anti-Spike IgG Responses and COVID-19 Disease 645 Severity. J Infect Dis. 2022 Jan 29; jiac022. Huang Y, Nguyen AW, Hsieh CL, Silva R, Olaluwoye OS, Wilen RE, et al. Identification of a 646 67. 647 conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses 648 [Internet]. bioRxiv; 2021 [cited 2022 Jun 9]. p. 2021.01.31.428824. Available from: 649 https://www.biorxiv.org/content/10.1101/2021.01.31.428824v2 650 68. Duan J, Yan X, Guo X, Cao W, Han W, Qi C, et al. A human SARS-CoV neutralizing antibody 651 against epitope on S2 protein. Biochem Biophys Res Commun. 2005 Jul 22;333(1):186–93. Garrido JL, Medina MA, Bravo F, McGee S, Fuentes-Villalobos F, Calvo M, et al. IgG targeting 652 69. 653 distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential 654 COVID-19 disease outcomes. Cell Rep. 2022 May 31;39(9):110904.
- 655

656 Figure legends

657 Fig 1. Total Ig antibody responses to SARS-CoV-2 among hospitalized and ambulatory patients in the VA cohort.

- **658 a.** Demographic and clinical data of hospitalized (n = 10) vs. ambulatory (n = 42) patients.
- **b.** IgG responses to nucleoprotein in hospitalized and ambulatory patients with or without comorbidities.
- The dotted line represents the cut-off at 1.4.
- **661 c.** Total Ig levels against spike and nucleoprotein in hospitalized (n = 10) vs. ambulatory (n = 42) patients.
- AUC: area under the curve. The red line represents the median. The dotted line represents the cut-off, calculated as
- 663 mean + 3SD of 5 COVID-19-negative specimens.
- **664 d.** Total Ig levels against spike and nucleoprotein between patients with (n = 24) vs without (n = 28) comorbidities.

- The red line represents the median. The dotted line represents the cut-off, calculated as mean + 3SD of 5 COVID-19-
- 666 negative specimens.
- 667 e. Changes of spike-specific total Ig levels over time post-symptom onset.
- The dotted lines represent the linear regression 95% confidence bands.
- **f.** Changes of S2-specific total Ig levels over time post-symptom onset in hospitalized (n = 10, left) vs. ambulatory (n = 42,
- 670 right) patients.
- 671 The dotted lines represent the linear regression 95% confidence bands.
- 672 Fig 2. Neutralization activities against SARS-CoV-2 among hospitalized and ambulatory patients in the VA cohort.
- **673 a.** Neutralization titers in sera of ambulatory (n = 42) vs. hospitalized (n = 10) patients.
- 674 The red line represents the median. Negative is set at 10, the lowest reciprocal dilution.
- **b**. Neutralization titers in sera of patients with (n = 24) vs. without (n = 31) comorbidities.
- 676 The red line represents the median. Negative is set at 10, the lowest reciprocal dilution.
- 677 c. Spearman correlation between neutralization titers and age of patients.
- 678 d. Changes in neutralization titers over time post-symptom onset.
- The dotted lines represent the linear regression 95% confidence bands.

680 Fig 3. Antibody isotypes against SARS-CoV-2 in sera of matched hospitalized vs. ambulatory VA patients.

- 681 The levels of spike-specific IgM, IgG1-4, IgA1 and IgA2 were measured in sera from matched hospitalized vs. ambulatory
- 682 patients.
- 683 The data are represented as mean fluorescent intensity (MFI) at a 1:200 serum dilution, each sample was tested in duplicate.
- 684 The dotted line represents the cut-off.
- 685 Statistical significance was calculated by a Wilcoxon matched-pairs test; each hospitalized patient was compared to 2 or 3
- 686 matched ambulatory patients.

687 Fig 4. Fab-mediated neutralization and Fc-mediated activities of SARS-CoV-2-specific antibodies in sera from matched

- 688 hospitalized and ambulatory VA patients.
- **a**. Neutralization activities in matched hospitalized vs. ambulatory patients. IC_{50} .: reciprocal serum titers yielding 50%
- 690 neutralization.
- **b**. Spike-specific ADCP activities in matched hospitalized vs. ambulatory patients.
- 692 c. C1q binding to spike-specific antibodies in matched hospitalized vs. ambulatory patients.
- 693 d. C3d binding to spike-specific antibodies in matched hospitalized vs. ambulatory patients.

- 694 AUC: area under the titration curve.
- 695 Statistical significance was calculated by a Wilcoxon matched-pairs test: six specimens from hospitalized patients were
- 696 compared to the average of 2 or 3 matched specimens from ambulatory patients.
- 697 ns: not significant (p >0.05).

698 Fig 5. Correlations of binding and functional Ab levels in matched hospitalized and ambulatory VA patients.

- 699 Spearman correlation matrix of serum Ab binding levels and functional activities were generated to compare matched (a)
- hospitalized (n = 6) vs. (b) ambulatory (n = 14) patients.

701 Fig 6. Differential cytokine/chemokine responses among hospitalized vs. ambulatory VA patients.

- 702 Statistically different responses in infected vs. negative individuals (a), hospitalized vs. ambulatory patients (b) and matched
- 703 hospitalized vs. ambulatory patients (c) were indicated by color codes.
- 704 Statistical significance was calculated by unpaired (**a**, **b**) or paired (**c**) non-parametric t-test. Significance was similarly
- achieved with other tests (parametric t-test and non-parametric Mann Whitney Wilcoxon in R).

706 Fig 7. Cytokines responses among hospitalized and ambulatory VA patients.

- 707 Data from three cytokines (IL-27, IL-4, and FGF-2 are presented as examples to show similarities and differences between
- hospitalized vs. all ambulatory patients (a, c, e) or between matched hospitalized vs. ambulatory patients (b, d, f). Statistical
- significance was calculated in GraphPad Prism by unpaired (**a**, **c**, **e**) or paired (**b**, **d**, **f**) non-parametric t-test (*: p<0.05, **:
- 710 p<0.01, ns: p>0.05). Significance was similarly achieved with parametric t-test and non-parametric Mann Whitney Wilcoxon in
- 711 R.

712 Supplemental Fig 1. Total Ig antibody responses to SARS-CoV-2 among hospitalized and ambulatory VA patients.

- 713 **a.** Total Ig levels against RBD, S1 and S2 in hospitalized (n = 10) vs. ambulatory (n = 42) patients.
- AUC: area under the titration curve. The red line represents the median. The dotted line represents the cut-off, calculated as
- 715 mean + 3SD of 5 COVID-19-negative specimens.
- 716 **b.** Total Ig levels against RBD, S1 and S2 between patients with (n = 24) vs. without (n = 28) comorbidities.
- 717 The red line represents the median. The dotted line represents the cut-off, calculated as mean + 3SD of 5 COVID-19-negative
- 718 specimens.
- 719 c. Changes of RBD-, S1-, S2-, and nucleoprotein-specific total Ig levels over time post-symptom onset.
- The dotted lines represent the linear regression 95% confidence bands.

721 Supplemental Fig 2. RBD-specific antibody isotypes in sera of matched hospitalized and ambulatory VA patients.

RBD-specific IgM, IgG1-4, IgA1 and IgA2 levels were measured in sera from matched hospitalized vs. ambulatory patients.

- 723 The data are presented as mean fluorescent intensity (MFI) at a 1:200 serum dilution. Each sample was tested in duplicate. The
- 724 dotted line represents the cut-off.
- 725 Statistical significance was calculated by a Wilcoxon matched-pairs test; each hospitalized patient was compared to 2 or 3
- 726 matched ambulatory patients.

727 Supplemental Fig 3. Fc-mediated activities of RBD-specific antibodies in sera from matched hospitalized and

- 728 ambulatory VA patients.
- a. C1q binding to RBD-specific antibodies in matched hospitalized vs. ambulatory patients.
- 730 **b.** C3b binding to RBD-specific antibodies in matched hospitalized vs. ambulatory patients.
- AUC: area under the titration curve. Statistical significance was calculated by a Wilcoxon matched-pairs test: each hospitalized
- patient was compared to 2 or 3 matched specimens from ambulatory patients.

733 Supplemental Fig 4. Differential cytokine/chemokine responses in sera of COVID-19-positive vs. -negative VA patients.

- Forty-eight cytokines and chemokines were measured in serum specimens from COVID-19-positive (n = 52) vs. negative (n =
- 735 28).
- 736 Data are shown as concentration in pg/mL (log10). Red line represents median. Highlighted red boxes show cytokines or
- 737 chemokines with significant differences (*: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001), calculated by unpaired non-
- 738 parametric t-test (GraphPad Prism). Significance was similarly achieved with parametric t-test and non-parametric Mann
- 739 Whitney Wilcoxon in R.

740 Supplemental Fig 5. Levels of cytokines and chemokines in sera of COVID-19 VA patients over time.

- 741 Changes of pg/mL concentrations of 11 cytokines (shown in Fig 5 to be statistically different between COVID-19-positive and
- 742 –negative individuals) + IL-4 and IL-27 over time post-symptom onset.
- The dotted lines represent the linear regression 95% confidence bands.

744 Supplemental Fig 6. Differences in the levels of cytokines and chemokines among hospitalized and ambulatory VA

- 745 patients.
- The levels of cytokines/chemokines were measured in sera from hospitalized (n = 10) vs. ambulatory (n = 42) patients.
- a. The data are shown as pg/mL concentration in log10. The gray line represents the median. The highlighted red boxes show
- the cytokines with significant differences between two patient groups (*: p<0.05, **: p<0.01), calculated by unpaired non-
- 749 parametric t-test (GraphPad Prism). Significance was similarly achieved with parametric t-test and non-parametric Mann
- 750 Whitney Wilcoxon in R.
- **b**. The data are shown as median modified Z scores. p value was obtained from one-side t test comparing median values of all

752 cytokines/chemokines in hospitalized vs. ambulatory groups.

753 Supplemental Fig 7. Correlations of cytokines and chemokines in hospitalized, ambulatory, and control patients.

- 754 Spearman correlation matrix of serum cytokines/chemokines levels were generated to compare hospitalized patients (n = 10),
- ambulatory patients (n = 42), and COVID-19-negative individuals (n = 28).

Figure 1

	Hospitalized n = 10	Ambulatory n = 42	Mann- Whitney test
Age Median (IQR)	68 (49-74)	62 (54-74)	p = 0.66 (ns)
Sample collection Median days post-onset (IQR)	178 (65-191)	188 (29-215)	p = 0.35 (ns)
% Male	100%	76%	
% White	40%	48%	
% Black and/or Hispanic	80%	83%	
% Black	50%	52%	
% Hispanic	40%	43%	
% Subjects with comorbidity	40%	48%	





(a)



Figure 3











Figure 5





200000





(a)

All Infected	vs Negative
sCD40L	<0.0001
EGF	
Eotaxin	
FGF-2	0.002
FLT-3L	
Fractalkine	
G-CSF	
GM-CSF	
GROg	
IFN-α2	0.003
IFNv	
ΙΙ-1α	0.005
IL-16	0.000
II - 1RA	0 0003
II.2	0.0005
II_2	0.04
IL-5	0.04
16-4	
IL-5	
IL-0	
IL-7	
IL-8	
IL-9	
IL-10	
IL-12p40	
IL-12p70	
IL-13	
IL-15	0.004
IL-17A	0.02
IL-17E/IL-25	<0.0001
IL-17F	
IL-18	
IL-22	
IL-27	
IP-10	
MCP-1	
MCP-3	
M-CSF	0.02
MDC	0.008
MIG/CXCL9	
MIP-1a	
ΜΙΡ-1β	
PDGF-AA	
PDGF-AB/BB	
RANTES	<0.0001
TGFα	
ΤΝFα	
τηγβ	
VEGF-A	

Figure 6

(b)

All Hospitalize	d vs Ambulatory
sCD40L	
EGF	
Eotaxin	
FGF-2	
FLT-3L	
Fractalkine	
G-CSF	
GM-CSF	
GROα	
IFN-α2	
IFNγ	
IL-1α	
IL-1β	
IL-1RA	
IL-2	i i
IL-3	1
IL-4	0.002
IL-5	
IL-6	
IL-7	
IL-8	
IL-9	
IL-10	
IL-12p40	
IL-12p70	
IL-13	
IL-15	
IL-17A	
IL-17E/IL-25	
IL-17F	
IL-18	
IL-22	
IL-27	0.02
IP-10	
MCP-1	
MCP-3	
M-CSF	İ
MDC	1
MIG/CXCL9	
MIP-1α	
MIP-1β	İ
PDGF-AA	1
PDGF-AB/BB	
RANTES	
TGFα	
ΤΝΓα	
τηγβ	
VEGF-A	
	1

Higher, p<0.0001	Lower, p<0.0001
Higher, p<0.001	Lower, p<0.001
Higher, p<0.01	Lower, p<0.01
Higher, p<0.05	Lower, p<0.05
ns	ns

(c)

Matched Hospitalized vs Ambulatory	
sCD40L	
EGF	
Eotaxin	
FGF-2	
FLT-3L	
Fractalkine	
G-CSF	
GM-CSF	
GROα	
IFN-α2	
IFNγ	
IL-1α	
IL-1β	
IL-1RA	
IL-2	
IL-3	
IL-4	
IL-5	
IL-6	
IL-7	
IL-8	
IL-9	
IL-10	
IL-12p40	
IL-12p70	
IL-13	
IL-15	
IL-17A	
IL-17E/IL-25	
IL-17F	
IL-18	
IL-22	
IL-27	0.03
IP-10	
MCP-1	
MCP-3	
M-CSF	
MDC	
MIG/CXCL9	
MIP-1α	
MIP-1β	
PDGF-AA	
PDGF-AB/BB	
RANTES	
TGFα	
ΤΝΓα	
τνεβ	
VEGF-A	



Matched specimens

Log10(concentration in pg/mL)